Бесплатная главастраницы PDF 37–44

1. Патофизиология ЦСХР

В оригинале: 1 Pathophysiology of CSCR

Из книги «Центральная серозная хориоретинопатия». Перевод главы на русский открыт всем без входа и подписки.

Содержание главы
  1. Глава 1. Патофизиология ЦСХРП
  2. Введение
  3. Механизмы изменений сосудистой оболочки: пахихориоидея
  4. Пигментный эпителий сетчатки (ПЭС)
  5. Изменения нейроретины
  6. Исходное место поражения
  7. Генетическая гипотеза
  8. Гипотеза минералокортикоидного пути
  9. Каковы последствия активации пути МР в ПЭС и сосудистой оболочке?
  10. Есть ли доказательства активации пути МР при ЦСХРП?
  11. Заключение
  1. 25. Starita C, Hussain AA, Patmore A, Marshall J. Localization of the site of major resistance to fluid transport in Bruch’s membrane. Invest Ophthalmol Vis Sci. 1997;38(3):762–767.
  2. 26. Sivaprasad S, Bailey TA, Chong VNH. Bruch’s membrane and the vascular intima: is there a common basis for age-related changes and disease? Clin Exp Ophthalmol. 2005;33(5):518–523.
  3. 27. Yu L, Shao Y, Chai Y, et al. Retinal microvasculature alteration in central serous chorioretinopathy. Mol Med Rep. 2018;17(2):2335–2340.
  4. 28. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica. 2001;215(3):183–187.
  5. 29. Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. Pachychoroid: an inherited condition? Retina Phila PA. 2015;35(1):10–16.
  6. 30. van Dijk EHC, Schellevis RL, van Bergen MGJM, et al. Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. JAMA Ophthalmol. 2017;135(5):446–451.
  7. 31. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J. 2010;24(9):3405–3415.
  8. 32. Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev. 2016;68(1):49–75.
  9. 33. Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature. Am J Nephrol. 2017;46(4):298–314.
  10. 34. Martín-Fernández B, Rubio-Navarro A, Cortegano I, et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. PLoS ONE. 2016;11(1):e0145946.
  11. 35. Funder J. 30 Years of the mineralocorticoid receptor: mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history. J Endocrinol. 2017;234(1):T17–T21.
  12. 36. Kolkhof P, Jaisser F, Kim S-Y, Filippatos G, Nowack C, Pitt B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305.
  13. 37. Davel AP, Anwar IJ, Jaffe IZ. The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease. Curr Opin Nephrol Hypertens. 2017;26(2):97–104.
  14. 38. Behar-Cohen F, Zhao M. Corticosteroids and the retina: a role for the mineralocorticoid receptor. Curr Opin Neurol. 2016;29(1):49–54.
  15. 39. Yang D, Eliott D. Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Semin Ophthalmol. 2017;32(1):36–42.
  16. 40. Kapoor KG, Wagner AL. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res. 2016;56(1):17–22.
  17. 41. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina Phila PA. 2013;33(10):2096–2102.
  18. 42. Daruich A, Matet A, Dirani A, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5(2):2.
  19. 43. Bousquet E, Beydoun T, Rothschild P-R, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina Phila PA. 2015;35(12):2505–2515.
  20. 44. Dutzmann J, Bauersachs J, Sedding DG. Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. Vasc Pharmacol. 2017.
  21. 45. van der Heijden CDCC, Deinum J, Joosten LAB, Netea MG, Riksen NP. The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovasc Res. 2018;114(7):944–953.
  22. 46. Juruena MF, Werne Baes CV, Menezes IC, Graeff FG. Early life stress in depressive patients: role of glucocorticoid and mineralocorticoid receptors and of hypothalamic-pituitary-adrenal axis activity. Curr Pharm Des. 2015;21(11):1369–1378.
  23. 47. Derijk RH, van Leeuwen N, Klok MD, Zitman FG. Corticosteroid receptor-gene variants: modulators of the stress-response and implications for mental health. Eur J Pharmacol. 2008;585(2–3):492–501.
  24. 48. Lee H-A, Song M-J, Seok Y-M, Kang S-H, Kim S-Y, Kim I. Histone deacetylase 3 and 4 complex stimulates the transcriptional activity of the mineralocorticoid receptor. PLoS One. 2015;10(8):e0136801.

Продолжение — после полного перевода

Это конец бесплатной главы. Остальные главы книги на русском пока не опубликованы: полного перевода на сайте нет, поэтому продолжение закрыто для всех читателей.

Войдите, чтобы заказать полный перевод

Заказ привязан к вашему аккаунту, чтобы повторные нажатия не создавали второй перевод.

К карточке книги и оглавлению